OBJECTIVE: To examine whether reimbursement for Provider Counseling, Pharmacotherapies, and a telephone Quitline increase smoking cessation relative to Usual Care. STUDY DESIGN: Randomized comparison trial testing the effectiveness of four smoking cessation benefits. SETTING: Seven states that best represented the national population in terms of the proportion of those > or = 65 years of age and smoking rate. PARTICIPANTS: There were 7,354 seniors voluntarily enrolled in the Medicare Stop Smoking Program and they were followed-up for 12 months. INTERVENTION(S): (1) Usual Care, (2) reimbursement for Provider Counseling, (3) reimbursement for Provider Counseling with Pharmacotherapy, and (4) telephone counseling Quitline with nicotine patch. MAIN OUTCOME MEASURE: Seven-day self-reported cessation at 6- and 12-month follow-ups. PRINCIPAL FINDINGS:Unadjusted quit rates assuming missing data=smoking were 10.2 percent (9.0-11.5), 14.1 percent (11.7-16.5), 15.8 percent (14.4-17.2), and 19.3 percent (17.4-21.2) at 12 months for the Usual Care, Provider Counseling, Provider Counseling + Pharmacotherapy, and Quitline arms, respectively. Results were robust to sociodemographics, smoking history, motivation, health status, and survey nonresponse. The additional cost per quitter (relative to Usual Care) ranged from several hundred dollars to $6,450. CONCLUSIONS: A telephone Quitline in conjunction with low-cost Pharmacotherapy was the most effective means of reducing smoking in the elderly.
RCT Entities:
OBJECTIVE: To examine whether reimbursement for Provider Counseling, Pharmacotherapies, and a telephone Quitline increase smoking cessation relative to Usual Care. STUDY DESIGN: Randomized comparison trial testing the effectiveness of four smoking cessation benefits. SETTING: Seven states that best represented the national population in terms of the proportion of those > or = 65 years of age and smoking rate. PARTICIPANTS: There were 7,354 seniors voluntarily enrolled in the Medicare Stop Smoking Program and they were followed-up for 12 months. INTERVENTION(S): (1) Usual Care, (2) reimbursement for Provider Counseling, (3) reimbursement for Provider Counseling with Pharmacotherapy, and (4) telephone counseling Quitline with nicotine patch. MAIN OUTCOME MEASURE: Seven-day self-reported cessation at 6- and 12-month follow-ups. PRINCIPAL FINDINGS: Unadjusted quit rates assuming missing data=smoking were 10.2 percent (9.0-11.5), 14.1 percent (11.7-16.5), 15.8 percent (14.4-17.2), and 19.3 percent (17.4-21.2) at 12 months for the Usual Care, Provider Counseling, Provider Counseling + Pharmacotherapy, and Quitline arms, respectively. Results were robust to sociodemographics, smoking history, motivation, health status, and survey nonresponse. The additional cost per quitter (relative to Usual Care) ranged from several hundred dollars to $6,450. CONCLUSIONS: A telephone Quitline in conjunction with low-cost Pharmacotherapy was the most effective means of reducing smoking in the elderly.
Authors: S M Hall; K L Delucchi; W F Velicer; C W Kahler; J Ranger-Moore; D Hedeker; J Y Tsoh; R Niaura Journal: Nicotine Tob Res Date: 2001-08 Impact factor: 4.244
Authors: D E Jorenby; S J Leischow; M A Nides; S I Rennard; J A Johnston; A R Hughes; S S Smith; M L Muramoto; D M Daughton; K Doan; M C Fiore; T B Baker Journal: N Engl J Med Date: 1999-03-04 Impact factor: 91.245
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Nancy A Rigotti; Virginia P Quinn; Victor J Stevens; Leif I Solberg; Jack F Hollis; Abby C Rosenthal; Jane G Zapka; Eric France; Nancy Gordon; Sabina Smith; Mina Monroe Journal: Eff Clin Pract Date: 2002 May-Jun
Authors: Kathryn L Taylor; Charlotte J Hagerman; George Luta; Paula G Bellini; Cassandra Stanton; David B Abrams; Jenna A Kramer; Eric Anderson; Shawn Regis; Andrea McKee; Brady McKee; Ray Niaura; Harry Harper; Michael Ramsaier Journal: Lung Cancer Date: 2017-02-15 Impact factor: 5.705
Authors: Kathryn L Taylor; Danielle E Deros; Shelby Fallon; Jennifer Stephens; Emily Kim; Tania Lobo; Kimberly M Davis; George Luta; Jinani Jayasekera; Rafael Meza; Cassandra A Stanton; Raymond S Niaura; David B Abrams; Brady McKee; Judith Howell; Michael Ramsaier; Juan Batlle; Ellen Dornelas; Vicky Parikh; Eric Anderson Journal: Contemp Clin Trials Date: 2019-05-23 Impact factor: 2.226
Authors: James G Xenakis; Elizabeth T Kinter; K Jack Ishak; Alexandra J Ward; Jeno P Marton; Richard J Willke; Simon Davies; J Jaime Caro Journal: Pharmacoeconomics Date: 2011-06 Impact factor: 4.981
Authors: Elyse R Park; Jamie S Ostroff; William Rakowski; Ilana F Gareen; Michael A Diefenbach; Sandra Feibelmann; Nancy A Rigotti Journal: Ann Behav Med Date: 2009-08-27